The creation of spin-offs at the IGTP has allowed innovative proposals to be developed towards products of commercial and social interest. The IGTP Innovation Unit analyzes the possibilities that each project has of achieving the objective of reaching patients by becoming part of the market.

Here we present the spin-offs that have emerged from our research projects:

  • Manremyc

    Manremyc is an IGTP spin-off founded in 2013 with the aim of exploring the health properties of environmental mycobacteria. It recently achieved a positive evaluation from the European Food Safety Agency (EFSA) for the characterization of heat-inactivated Mycobacterium manresensis, a product that is also Halal certified. Manremyc belongs to the B Corp community.

  • Innovex Therapeutics S.L.

    Innovex Therapeutics S.L. is a biotechnology company that uses Extracellular Vesicles as Vaccines against infectious diseases with the goal of achieving global health equity. Innovex has developed an innovative exosome-based vaccine platform featuring a novel antigen-determinant discovery technology that has been shown to elicit specific IgG responses and long-lived effector memory T-cell responses.

  • Aniling – accelerating epigenomics

    Aniling is a spin-off committed to bringing advances in the genomics arena to everyday health care and disease prevention. Aniling's goal is to accelerate epigenomics to help make precision medicine a reality. The company has patented the GEUS technology (Genomic and Epigenomic Unified Sequencing), which allows for the first-time simultaneous and high-reliability analysis of genome and epigenome, and provides end-to-end solutions for the right treatment decisions in oncology.

  • Ahead Therapeutics - Fighting Autoimmune Diseases

    Ahead Therapeutics is a biotech company developing an antigen-specific biomimetic treatment for autoimmune diseases. Ahead has a proprietary nano-technology platform to generate Antigen-Specific Immune Tolerance and mimic engulfment of apoptotic cells. The company's pipeline embraces Type 1 Diabetes, Multiple Sclerosis, Celiac Disease, Rheumatoid Arthritis; Myasthenia Gravis; Neuromyelitis Optica, and Anti-synthetase syndrome, amongst others.

  • Changing the paradigm in Friedreich's ataxia

    Biointaxis, an IGTP spin-off established in 2018, which develops BTX-101, an exclusive patented gene therapy product, based on an adeno-associated virus (AAV) drug for the cure of Friedreich's ataxia, a progressive neurodegenerative genetic disorder caused by deficiency of the mitochondrial protein frataxin for which there is currently no treatment. BTX-101 has demonstrated its effectiveness in two mouse models of the disease by restoring frataxin levels in vivo, preventing, arresting and reversing the neurological and cardiac deficits which are the main clinical signs associated with Friedreich's ataxia.

  • TIB - Time is brain

    Time is Brain is a technology-based spin-off founded by neurologists of the IGTP, which is developing BraiN20, a medical device that improves the prognosis of acute ischemic stroke. The revolutionary medical device is based on real-time somatosensory evoked potential monitoring for the triage of acute ischemic stroke patients suitable for mechanical thrombectomy treatment.

  • BREAZ: Detecting breathing diseases early

    Breaz is a deep-tech company focused on creating new solutions for respiratory diseases. Breaz is developing a medical device based on new sensors and using AI, with the aim of changing the way respiratory diseases are diagnosed, making testing easier and more accessible for patients and health professionals. With better diagnosis and monitoring, the company aims to reduce the devastating impact these diseases have on patients, health systems and society.

  • Nimble Diagnostics

    Nimble Diagnostics is a spin-off that is developing microwave-based technology to monitor stents implanted in patients with cardiovascular, vascular, kidney or lung diseases. The Nimble system facilitates preventive care and eliminates the need for invasive procedures, X-ray radiation and hospitalization. The device allows doctors to obtain precise results rapidly and it is completely non-invasive, painless and easy to use.

  • AIMS-Medical

    AIMS-Medical is an IA-based spin-off founded by researchers of the CSdM, committed to developing cutting-edge technologies that empower medical professionals to improve diagnosis and manage age-related illnesses. The ultimate goal of the company is to transform the way healthcare providers approach the management of age-related illnesses, using technology to provide real-time, systematic and universal diagnosis of these conditions.